Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
Kymera Therapeutics presented new preclinical data for KT-579, its first-in-class oral IRF5 degrader, at the EULAR and FOCIS annual meetings. The data demonstrated disease-modifying activity in multiple lupus models that was comparable or superior to approved and clinically active therapies.
Key figures
- Drug Name
- KT-579
- Phase Of Trial
- Phase 1
- Phase1 data expected
- 2H26
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.